Canurta Expands Global Reach Through Premier Conferences and Advances ALS Research
- Canurta
- Jan 31, 2024
- 3 min read
CEO Akeem Gardner to Speak at CannMed Innovation and Investment Summit on New Treatments for Neurological Disorders
Our Founder & CEO Akeem Gardner is scheduled to speak at the CannMed Events Innovation and Investment Summit in Marco Island, FL on May 14, 2024. His talk is titled: Effect of Cannflavins on Mitigating Motor Neuron Diseases.
"Encouraged by the favourable impact of cannflavins in an initial screening involving mutant Caenorhabditis elegans models for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, our research group opted to further investigate the potential effects of both cannflavins and cannabinoids in alleviating neuro-motor ailments."
Read more about our groundbreaking research focus here:
Canurta Accepted into the Cannabis Innovation Lab, A Private Community of Tech Founders and VCs
We are very excited to share that Canurta has been accepted into 1871's Cannabis Innovation Lab winter 2024 cohort.
1871 inspires, equips, & supports extraordinary tech businesses. Their member base includes early, growth, and late stage startups & corporate innovators.
The Cannabis Innovation Lab connects startups with late-stage partners, corporates, VCs, and industry leaders to collaborate on solving industry problems for future transformation.
Canurta Participates in Arab Health 2024 at the Dubai World Trade Centre
Arab Health 2024, the intersection of cutting-edge technologies, revolutionary concepts and healthcare experts is reshaping the healthcare landscape.
The conference allowed for B2B meetings with companies and service providers that can aid in opening up the Gulf-UAE markets for Canurta given the niche area of research and product development industrial hemp has in the region.
CEO Akeem Gardner also visited Dr. Murad Mustafa, the world-renowned Head of the Veterinary Hospital at Dubai Safari Park to discuss developing a research project studying the efficacy of our products in treating inflammation and reducing inflammatory biomarkers in their animals.
This was an important meeting for opening the Middle Eastern markets for Canurta by way of research with one of the 2015 Winners of the Hamdan Bin Mohammed Award for Smart Government for Best Service Star Category.
Canurta attended the JP Morgan Healthcare Conference in San Francisco
Canurta kicked off the year by heading to San Francisco for the largest and most informative health care investment week in the industry, connecting global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
Invited by the Ontario Trade Mission to BIO International, this exclusive conference was filled with numerous events held by private investment groups, and Canurta’s participation marks its rise as an emerging biotechnology company.
Canurta participated in B2B and investor meetings while discussing current trends in M&A, the impact of economic factors on healthcare investments, innovation in AI and machine learning for our industry.
Canurta's January Milestones
Research & Development
ALS Formulation Progress: Positive results for CNR-401 in our research team's zebrafish ALS model.
Bioinformatics
New Datasets from ALS Patients: Our dedication to the fight against ALS continues to yield remarkable results. This month, we meticulously analyzed multiple datasets containing diverse genetic information from ALS patients. Our thorough analysis revealed differentially expressed genes, that will significantly aid us in identifying potential biomarkers crucial for targeted treatments using Canurta's ingredients.
Moreover, we acquired the Answer ALS dataset, which holds invaluable information that will help us gain more insights, with the potential for making a tangible difference in combating this devastating disease.
